Table 1.
Administration route and dosing regimens of anti-CD20 mAbs in phase II/III clinical trials.
| Administration route | Rituximab (OLYMPUS) |
Rituximab (RIFUND-MS) |
Ocrelizumab (OPERA I/II) |
Ofatumumab (ASCLEPIOS I/II) |
Ublituximab (ULTIMATE I/II) |
|---|---|---|---|---|---|
| IV infusion | IV infusion | IV infusion | SC self-injection | IV infusion | |
| Dosing regimen | |||||
| First dose | 1 000 mg | 1 000 mg | 2 x 300 mg over ≥ 2.5 h | 20 mg | 150 mg over 4 h |
| Second dose and timing | 1 000 mg at week 2 |
2 x 300 mg over ≥ 2.5 h at week 2 | 20 mg at weeks 1 and 2 | 450 mg over 1 h on day 15 | |
| Subsequent doses and timing | 1 000 mg every 6 months | 500 mg every 6 months | 600 mg over ≥ 3.5 h or over ≥ 2 h every 6 months | Every month starting at week 4 | 450 mg over 1 h at weeks 24, 48 and 72 |
IV, intravenous; SC, subcutaneous.